Global Brain Imaging and Neuroimaging Market Research Report Information By Imaging Type [Functional Magnetic Resonance Imaging (FMRI), Compound Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magnetoencephalography (MEG) and Near Infrared Spectroscopy (NIRS)], By End User (Hospitals, Ambulatory Surgical Centers and Clinics and Diagnostic Centers) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Brain Imaging and Neuroimaging Market Overview

The Brain Imaging and Neuroimaging Market Size was valued at USD 13.2 Billion in 2022 and is projected to grow from USD 13.9 Billion in 2023 to USD 21.9 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.80% during the forecast period (2024 - 2032). Increasing frequency of neurological conditions is the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Brain Imaging and Neuroimaging Market Trends

Increasing frequency of neurological conditions is driving the market growth

One of the main factors propelling the market for brain imaging and neuroimaging growth is the rising prevalence of neurological disorders. The term "neurological conditions" refers to a broad category of illnesses affecting the brain and nervous system, such as stroke, multiple sclerosis, epilepsy, Parkinson's disease, Alzheimer's disease, and epilepsy. The increasing frequency of these disorders and, as a result, the increased need for brain imaging services are caused by a number of variables.

First and foremost, a major contributing factor to the rising incidence of neurological disorders worldwide is the aging population. The likelihood of having neurodegenerative illnesses like Alzheimer's and Parkinson's disease increases with age. The senior population is growing as a result of increased life expectancies brought about by advancements in healthcare and housing. The number of people at risk of developing these illnesses has increased as a result of the demographic shift, increasing the need for neuroimaging approaches for early identification and diagnosis.

Another element contributing to the rising incidence of neurological disorders is the environment. A number of neurological conditions, including motor neuron illnesses, have been related to exposure to environmental chemicals and pollution. People may be exposed to a greater spectrum of potential environmental risk factors as industrialization and urbanization continue, which could lead to an increase in the incidence of neurological diseases. Furthermore, improvements in diagnostic tools have made it possible for medical practitioners to identify neurological disorders with greater accuracy thanks to developments in medical science and the infrastructure supporting it. The apparent rise in the prevalence of certain illnesses can be attributed to the identification of previously undetected instances.

Recent years have also seen an increase in the understanding and identification of neurological illnesses. There are now more frequent medical consultations and diagnostic evaluations as a result of increased public and healthcare professional awareness of the symptoms and indicators of these disorders. Patient outcomes may be enhanced by the early detection and intervention brought about by this greater knowledge. Thus, driving the Brain imaging and neuroimaging market revenue.

Brain Imaging and Neuroimaging Market Segment Insights

Brain Imaging and Neuroimaging Imaging Type Insights

The Brain Imaging and Neuroimaging Market segmentation, based on imaging type, includes [functional magnetic resonance imaging (FMRI), compound tomography (CT), positron emission tomography (PET), electroencephalography (EEG), magnetoencephalography (MEG) and near infrared spectroscopy (NIRS)]. The functional magnetic resonance imaging (FMRI) segment dominated the market in 2022. The growing application of fMRI in neurological disease diagnosis and therapy, including epilepsy, Parkinson's disease, and Alzheimer's disease. In healthy people, fMRI is also used to investigate how the brain functions during learning and memory activities.

Brain Imaging and Neuroimaging End User Insights

The Brain Imaging and Neuroimaging Market segmentation, based on end user, includes hospitals, ambulatory surgical centers and clinics and diagnostic centers. The hospitals category generated the most income in 2022. Hospitals typically offer modern imaging technologies including CT (Computed Tomography), PET (Positron Emission Tomography), MRI (Magnetic Resonance Imaging), and SPECT (Single-Photon Emission Computed Tomography). The ability to precisely view the structure and functions of the brain thanks to these advancements aids in the diagnosis and treatment of neurological disorders. Hospitals and academic institutions often work together on research projects. They can set the standard for innovation and research in neuroimaging. They might take part in clinical studies, develop novel imaging techniques, and come up with creative uses for existing technologies.

Figure 1: Brain Imaging and Neuroimaging Market, by End User, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Brain Imaging and Neuroimaging Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Brain Imaging and Neuroimaging Market dominated this market in 2022 (45.80%). North America is home to globally recognized centers for neuroscience research and innovation. Prominent academic institutions including MIT and Harvard University work together on state-of-the-art brain imaging research in Boston, Massachusetts. This partnership drives technological progress and results in the creation of novel neuroimaging methods. Further, the U.S. Brain imaging and neuroimaging market held the largest market share, and the Canada Brain imaging and neuroimaging market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: BRAIN IMAGING AND NEUROIMAGING MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Brain imaging and neuroimaging market accounts for the second-largest market share. Institutions in Europe place a strong emphasis on multidisciplinary neuroscience research, encouraging partnerships between computer scientists, radiologists, neurologists, and psychologists. The multidisciplinary approach to neuroimaging at the Oxford Centre for Functional MRI of the Brain (FMRIB) in the United Kingdom is well-known. Further, the German Brain imaging and neuroimaging market held the largest market share, and the UK Brain imaging and neuroimaging market was the fastest growing market in the European region.

The Asia-Pacific Brain Imaging and Neuroimaging Market is expected to grow at the fastest CAGR from 2023 to 2032. There is an increasing need for neurological healthcare services as the region experiences demographic changes due to a fast aging population and a rise in non-communicable diseases. Japan is a prime example of this trend, as evidenced by the aging population there and the reliance on neuroimaging for geriatric care at institutions such as the National Center for Geriatrics and Gerontology. Moreover, China’s Brain imaging and neuroimaging market held the largest market share, and the Indian Brain imaging and neuroimaging market was the fastest growing market in the Asia-Pacific region.

Brain Imaging and Neuroimaging Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Brain imaging and neuroimaging market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Brain imaging and neuroimaging industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Brain imaging and neuroimaging industry to benefit clients and increase the market sector. In recent years, the Brain imaging and neuroimaging industry has offered some of the most significant advantages to medicine. Major players in the Brain imaging and neuroimaging market, including GE, Siemens, Canon, Hitachi Medical Systems, Medtronic PLC., EB Neuro S.p.A., Neurosoft, MinFound Medical Systems Co. Ltd., Elekta, Varian medical Systems, General Electric Company, Philips Healthcare, Toshiba Medical Systems, Sanrad medical Systems Pvt. Ltd, Esaote SpA and others, are attempting to increase market demand by investing in research and development operations.

Elekta AB (Elekta) is a medical technology firm that provides information systems, image guided clinical solutions, and services for the treatment of cancer and brain illnesses. Gamma knife and extend systems, volumetric arc modulated therapy, fully integrated stereotactic radiation therapy systems, advanced digital treatment systems, treatment planning systems, electronic brachy therapy for skin cancer, and automated remote after loading platform are some of its main products. The company provides, among other things, treatment planning software, cancer registry software, soft tissue imaging software, and oncology information systems for radiation and medical oncology. Moreover, it provides radiation therapy for animals. The business has operations throughout Asia-Pacific, Europe, the Middle East, Africa, and North America. Base of operations for Elekta is in Stockholm, Sweden.

Technology is the business of Siemens AG (Siemens). Its activities cover the domains of digitalization, automation, and electrification. The business creates, develops, and produces goods in addition to installing intricate projects and systems. Additionally, it offers a large selection of specially designed solutions to meet specific needs. Siemens specializes in distributed energy systems, intelligent building infrastructure, and power generation and distribution. Medical technology, digital healthcare services, and smart mobility solutions for road and rail transportation are all offered. Siemens maintains production sites, warehouses, sales offices, and research and development centers all around the world. It provides services to clients in a number of sectors, including manufacturing, infrastructure, energy, healthcare, and process. Bavaria, Germany's Munich serves as the home base for Siemens.

Key companies in the brain imaging and neuroimaging market include

• GE


• Siemens


• Canon


• Hitachi Medical Systems


• Medtronic PLC.


• EB Neuro S.p.A.


• Neurosoft


• MinFound Medical Systems Co. Ltd.


• Elekta


• Varian medical Systems


• General Electric Company


• Philips Healthcare


• Toshiba Medical Systems


• Sanrad medical Systems Pvt. Ltd


• Esaote SpA

Brain Imaging and Neuroimaging Industry Developments

March 2024: Philips and Synthetic MR have joined forces to improve the identification of neurological illnesses in the realm of medical diagnostics. They aim to achieve this by utilizing modern quantitative brain imaging methods. This collaboration seeks to transform the identification and examination of illnesses such as multiple sclerosis, traumatic brain injuries, and dementia.

June 2023: The software's maker, Ezra, claims that the Food and Drug Administration (FDA) authorized Ezra Flash (Ezra). Artificial intelligence software enhances the images obtained from a fast MRI procedure.

October 2022: GE Healthcare unveiled the Omni Legend positron emission tomography/computed tomography (PET/CT) platform at the European Association of Nuclear Medicine (EANM) in Barcelona. The platform's features, which are made possible by artificial intelligence (AI), include enhanced diagnostic capabilities and increased effectiveness.

September 2022: In collaboration with the University Of Miami Miller School Of Medicine, Qynapse Inc. is thrilled to announce the commencement of a research supported by the National Institutes of Health (NIH). The project will examine the impact of COVID-19 on the vascular factors that lead to dementia and cognitive impairment (VCID).

March 2022: The Indian Institute of Technology (IIT Madras) is home to the Sudha Gopala Krishnan Brain Centre, which was founded with a focus on high-resolution brain imaging and the cellular and connectivity maps of human brains. The state-of-the-art brain center aims to become a premier research facility by producing unprecedented volumes of data on the human brain, new scientific findings, and technology innovations.